Vekaria Sona, Kavanagh Grace, Mulrennan Siobhain
Department of Respiratory Medicine Sir Charles Gairdner Hospital Nedlands Western Australia Australia.
Department of Pharmacy Sir Charles Gairdner Hospital Nedlands Western Australia Australia.
Respirol Case Rep. 2025 Mar 24;13(3):e70146. doi: 10.1002/rcr2.70146. eCollection 2025 Mar.
Hepatotoxicity due to Elexacaftor/Tezacaftor/Ivacaftor (ETI) use has been well documented. There are no dose adjustments or increased-frequency monitoring algorithms recommended for people who experience elevated transaminases without cirrhosis, only suggested treatment interruption or withdrawal depending on the severity of the derangement. Here we describe a patient with non-cirrhotic hepatic steatosis who experienced persistently elevated liver function tests due to modulator therapy but demonstrated a remarkable response to a notably low dose of ETI.
使用依列卡福妥/替扎卡福妥/依伐卡福妥（ETI）导致肝毒性已有充分记录。对于转氨酶升高但无肝硬化的患者，目前没有推荐的剂量调整或增加监测频率的算法，仅根据肝功能紊乱的严重程度建议中断治疗或停药。在此，我们描述一名患有非肝硬化性肝脂肪变性的患者，该患者因调节剂治疗导致肝功能检查持续升高，但对低剂量的ETI表现出显著反应。
